Modafinil
- Generic Name
- Modafinil
- Brand Names
- Provigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 68693-11-8
- Unique Ingredient Identifier
- R3UK8X3U3D
- Background
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...
- Indication
To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
- Associated Therapies
- -
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06665230
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC (Site 0001), Knoxville, Tennessee, United States
A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
- Conditions
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06619665
- Locations
- 🇺🇸
NeuroTrials Research Inc (Site 0001), Atlanta, Georgia, United States
🇺🇸Clinilabs (Site 0003), Eatontown, New Jersey, United States
RECOVER-SLEEP: Platform Protocol
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1074
- Registration Number
- NCT06404086
- Locations
- 🇺🇸
University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 474
- Registration Number
- NCT06404099
- Locations
- 🇺🇸
All sites listed under NCT06404086, Durham, North Carolina, United States
Investigation of Locus Coeruleus Function in Sustained Attention
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 40
- Registration Number
- NCT06041048
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Kuwait University
- Target Recruit Count
- 30
- Registration Number
- NCT05675098
- Locations
- 🇰🇼
Physical Medicine and Rehabilitation Hospital, Kuwait, Kuwait
Modafinil to Improve Fatiguability
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05333250
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Modafinil for Wakefulness in the Critical Care Units
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2021-02-12
- Target Recruit Count
- 8
- Registration Number
- NCT04751227
- Locations
- 🇸🇦
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Treatment for Cognitive Impairment in Depression
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04317001
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT03864042
- Locations
- 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.